AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 55,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
108% more first-time investments, than exits
New positions opened: 258 | Existing positions closed: 124
47% more funds holding in top 10
Funds holding in top 10: 165 [Q4 2024] → 242 (+77) [Q1 2025]
15% more call options, than puts
Call options by funds: $3.94B | Put options by funds: $3.43B
14% more capital invested
Capital invested by funds: $232B [Q4 2024] → $264B (+$31.7B) [Q1 2025]
1% more funds holding
Funds holding: 3,676 [Q4 2024] → 3,726 (+50) [Q1 2025]
0.98% less ownership
Funds ownership: 72.04% [Q4 2024] → 71.07% (-0.98%) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 1,463 | Existing positions reduced: 1,581
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$205
7%
upside
Avg. target
$219
14%
upside
High target
$250
30%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Citigroup Geoff Meacham | 7%upside $205 | Neutral Downgraded | 14 May 2025 |
Guggenheim Vamil Divan | 12%upside $216 | Buy Maintained | 29 Apr 2025 |
Raymond James Gary Nachman | 18%upside $227 | Outperform Maintained | 28 Apr 2025 |
Evercore ISI Group Gavin Clark-Gartner | 7%upside $205 | Outperform Maintained | 28 Apr 2025 |
Morgan Stanley Terence Flynn | 30%upside $250 | Overweight Maintained | 28 Apr 2025 |
Financial journalist opinion
Based on 60 articles about ABBV published over the past 30 days
Negative
Zacks Investment Research
16 hours ago
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Positive
Seeking Alpha
18 hours ago
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.
Positive
The Motley Fool
23 hours ago
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend stocks.
Positive
Reuters
1 day ago
Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie
Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
Neutral
Zacks Investment Research
1 day ago
AbbVie (ABBV) Laps the Stock Market: Here's Why
AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.
Positive
Benzinga
1 day ago
Why Is AbbVie Stock Trading Higher On Thursday?
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.
Neutral
CNBC Television
1 day ago
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
The Investment Committee give you their top stocks to watch for the second half.
Positive
Reuters
1 day ago
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2001.
Neutral
GlobeNewsWire
1 day ago
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Neutral
PRNewsWire
1 day ago
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.
Charts implemented using Lightweight Charts™